Rheumnow Podcast

Dr. Cush
  • 4.7 (126)
  • Medicine
  • Updated Weekly

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

  1. 17h ago

    DERM on RheumNow (July 2026)

    The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026

    DERM on RheumNow (July 2026)

  2. 17h ago

    New, Advanced Therapies in Gout

    New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)

    New, Advanced Therapies in Gout

  3. 21h ago

    Systemic Burden of Gout Part 1

    Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout  Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?

    Systemic Burden of Gout Part 1

  4. 21h ago

    Better Gout Management

    Dr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity

  5. 21h ago

    Gout Advice & Tips

    Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome  Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout

  6. 21h ago

    Gout Lessons from the Clinic Part 2

    Dr Janet Pope: QD Clinic: Can RA and Gout Manifest Simultaneously?  Dr. Mrinalini Dey QD312: Gout, Sepsis… or Both?  Daric Mueller, PA-C QD315: Pegloticase Immunomodulation: What’s on the Menu?  Dr. Richard Conway: QD313: Don't Presume on IL-1 in Gout

    Gout Lessons from the Clinic Part 2

  7. 6d ago

    Chikungunya Club Meeting (7.24.2026)

    Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com

  8. Jul 22

    Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.)

    Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo  Dr. Lisa Stamp  Dr. Michael Pillinger  Dr. Ted Mikuls  Moderator: Dr. Jack Cush

    Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.)
See All (998)

4.7
out of 5
126 Ratings

About

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

Information

  • Creator
    Dr. Cush
  • Years Active
    2016 - 2026
  • Episodes
    998
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    Rheumnow Podcast